A single dose of psilocybin—the active compound in magic mushrooms—reduces nerve pain for up to a month and appears to permanently restructure how the brain processes pain itself, according to new research from the University of Reading published in Communications Biology. In mice with nerve damage, psilocybin's pain-relieving effect emerged about two hours after injection and persisted for several weeks, but what made the discovery even more significant was something unexpected: the compound seemed to reset the brain's pain networks in a way that made other medications far more effective long afterward.
Between 30% and 50% of people with nerve pain struggle to find relief from gabapentin alone, a widely prescribed painkiller that currently leaves millions without adequate control. The Reading team tested what would happen if psilocybin and gabapentin worked together. They gave mice a single dose of psilocybin, and then weeks later—once psilocybin's own pain-relieving effects had completely worn off—they administered gabapentin. The result was striking: in mice that had received psilocybin first, gabapentin produced pain relief lasting up to four days. In mice that had never received psilocybin, gabapentin's effect was dramatically weaker.
"Millions of people live with nerve pain that their medication simply does not control well enough, and the medicines we do have can cause serious side effects or lead to addiction," said Dr. Maria Maiarú, senior author of the study. "What is exciting here is that psilocybin does not just reduce pain on its own. It appears to reset the brain's pain networks in a way that makes existing treatments significantly more effective. For patients who have run out of options, that could be genuinely transformative."
Rather than working like conventional painkillers that simply block pain signals, psilocybin appears to work by fundamentally reorganizing the pain-processing networks in the brain—which may explain why its effects linger long after the drug itself has been metabolized and left the body. This distinction matters enormously for patients, because it suggests the benefit isn't fleeting, but rather a lasting change in how their nervous system processes pain signals.
The research team also confirmed that the pain-relieving effect worked equally well in both male and female mice, a detail that speaks to more rigorous science. Much early pain research was conducted only in male animals, potentially missing important variations in how different populations respond to treatment. The study used a small number of mice in line with U.K. Home Office regulations and the 3Rs principles—replacement, reduction, and refinement—with procedures designed to minimize distress and multiple outcomes measured from the same animals to keep overall numbers down.
For the millions of people living with chronic nerve pain that resists conventional treatment, the implications are profound. This isn't a silver bullet—it's a potential bridge. One dose might prime the brain's pain systems to work better with medications that currently fall short. The University of Reading team has opened a door toward treatments that don't just mask symptoms but fundamentally alter how the nervous system responds to pain.